Rare lephants
Screener

CNBX Pharmaceuticals Inc.

CNBX ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — CNBX Pharmaceuticals Inc.

Total Moat Score 2 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 2 / 5 Holds patent-pending sustained-release cannabinoid formulation technology and early peer-reviewed pilot data in cancer anorexia-cachexia, but IP is unproven at scale and not yet FDA-validated.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 No manufacturing or production operations exist; CMC work is fully outsourced, so there is no structural cost advantage versus competitors.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 0 / 5 Pre-revenue with no approved or commercialized products, so the company has no pricing power of any kind.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 A single-product-pipeline biotech with no platform, user base, or data network effects.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 0 / 5 No customers, prescribers, or patients are yet using any product, so no switching costs have been established.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 0 / 5 Essentially a one-employee operation with an unfunded ~$6.5 million clinical program; far too small to benefit from scale economics.